(NASDAQ:DWTX),(HKSE:0775),(HKSE:0775.HK), Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into […]

(NASDAQ:MYGN), SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation

(NasdaqGM:IRON), Bitopertin was awarded the Commissioner's National Priority Review Voucher (CNPV) and NDA is currently under FDA review Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026, followed by an End of Phase 2 Meeting Initial data from the ongoing Phase 2 study of

(NasdaqGM:XENE), Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026 Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications in epilepsy and neuropsychiatry; Phase 3 X-NOVA2 topline data in MDD expected in H1 2027 Data from two Phase 1 studies

(NasdaqGM:NEWT), BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — NewtekOne, Inc. (the “Company”) (NASDAQ: NEWT) will report its fourth quarter 2025 financial results after the market closes on Thursday, January 29, 2026. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer, and Frank DeMaria, Chief Financial Officer,

(NASDAQ:ALHC), Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million in 2026 will be within its full-year 2026 guidance range. Reaffirms its full-year 2025 guidance ranges on health plan membership, revenue, adjusted gross profit and adjusted EBITDA. ORANGE, Calif., Jan. 12, 2026

(TSX-V:LMS),(OTC US:LMSQF),(Other OTC:LMSQF), VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Latin Metals Inc. (“Latin Metals” or the “Company“) (TSXV: LMS) (OTCQB: LMSQF) is pleased to provide shareholders with an overview of project advancement achieved during 2025 and the exploration and corporate activities planned for 2026, as the Company transitions from project advancement to

(NASDAQ:TTMI), SANTA ANA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — TTM Technologies, Inc. (NASDAQ: TTMI) (“TTM”), a leading global manufacturer of technology products, including mission systems, radio frequency (“RF”) components, RF microwave/microelectronic assemblies, and technologically advanced printed circuit boards (“PCB”s), is proud to announce that its Syracuse Campus has been named the winner of the

(NASDAQ:CLOV), SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Counterpart Health, Inc. (“Counterpart” or the “Company”), a leading AI-powered physician-enablement platform and subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), today released key 2025 highlights. The past year was defined by continued publication of research demonstrating the platform's impact on chronic disease management, meaningful product

(TSX:LYUV.U),(TSX:LYUV-U), TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Lysander Funds Limited (“Lysander“) is excited to announce the launch of an exchange-traded fund series of units (“ETF Series“) of Lysander-Canso U.S. Corporate Value Bond Fund (the “Fund“). The portfolio manager of the Fund is Canso Investment Counsel Ltd. (“Canso“). The ETF Series of the Fund will